Remibrutinib CSU Submissions shifting to 2025
https://www.novartis.com/sites/novartis_com/files/q2-2024-investor-presentation.pdf
Page 17
https://www.novartis.com/sites/novartis_com/files/q2-2024-investor-presentation.pdf
Page 17
-
Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page
This company never gets anything done on time. There is always an issue somewhere. Time to become leaner, agile and hold people accountable!Remibrutinib CSU Submissions shifting to 2025
https://www.novartis.com/sites/novartis_com/files/q2-2024-investor-presentation.pdf
Page 17
Remibrutinib CSU Submissions shifting to 2025
https://www.novartis.com/sites/novartis_com/files/q2-2024-investor-presentation.pdf
Page 17
It’s not the holy grail some believe it is. Watch the forecast being adjusted downward in the coming months.
Product delays? Welcome to the family!Remibrutinib CSU Submissions shifting to 2025
https://www.novartis.com/sites/novartis_com/files/q2-2024-investor-presentation.pdf
Page 17
-Leqvio
For the US market I would not expect a great delay. Voucher could be applied. Nevertheless, minimum 2 billion peak sales and 40% operational gross profit might become a challenge. If Remi fails in MS, business case could no longer fit.